Horst HE. Prognosis of fatigue and func- tioning in primary care: a 1-year follow-up study. Ann Fam Med. 2008;6(6):519-527.


5. Gunja N, Brown JA. Energy drinks: health risks and toxicity. Med J Aust. 2012;196(1):46-49.


6. Arria AM, Caldeira KM, Kasperski SJ, Vincent KB, Griffiths RR, O'Grady KE. En- ergy drink consumption and increased risk for alcohol dependence. Alcohol Clin Exp Res. 2011;35(2):365-375. doi: 10.1111/j.1530- 0277.2010.01352.x. Epub 2010.


7. Michelfelder AJ, Lee KC, Bading EM. Integrative medicine and gastrointestinal disease. Prim Care. 2010 ;37(2):255-267. Re- view.


8. Wilson S, Roberts L, Roalfe A, Bridge P, Singh S. Prevalence of irritable bowel syn- drome: a community survey. Br J Gen Pract. 2004;54(504):495-502.


9. Oberndorff-Klein Woolthuis AH, Brum- mer RJ, de Wit NJ, Muris JW, Stockbrügger RW. Irritable bowel syndrome in general practice: an overview. Scand J Gastroen- terol Suppl. 2004;241:17-22.


10. Ott SJ, Musfeldt M, Wenderoth DF, Hampe J, Brant O, Fölsch UR, Timmis KN, Schreiber S.Reduction in diversity of the colonic mucosa associated bacterial micro- flora in patients with active inflammatory bowel disease. Gut. 2004;53(5):685-93.


11. Kroemer G, Galluzzi L, Brenner C. Mi- tochondrial Membrane Permeabilization in Cell Death. Physiol Rev. 2007;87:99–163.


12. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rab- inovitch M, Cernadas M, Kim HP, Fitzger- ald KA, Ryter SW, Choi AM. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflam- masome. Nat Immunol. 2011;12(3):222- 2230. Epub 2010 Dec 12.


13. Franchi L, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13(4):325-332. doi: 10.1038/ni.2231.


14. Chen GY, Núñez G. Inflammasomes in intestinal inflammation and cancer. Gas- troenterology. 2011;141(6):1986-1699. Epub 2011 Oct 15.


15. Stienstra R, van Diepen JA, Tack CJ, Zaki MH, van de Veerdonk FL, Perera D, Neale GA, Hooiveld GJ, Hijmans A, Vroegrijk I, van den Berg S, Romijn J, Rensen PC, Joos- ten LA, Netea MG, Kanneganti TD. Inflam- masome is a central player in the induction of obesity and insulin resistance. Proc Natl Acad Sci U S A. 2011;108(37):15324-15329. Epub 2011 Aug 29.


16. Bansal AS, Bradley AS, Bishop KN, Ki- ani-Alikhan S, Ford B. Chronic fatigue syn- drome, the immune system and viral infec- tion. Brain Behav Immun. 2012;26(1):24-31. Epub 2011 Jul 2.


18 Focus August 2012


17. Maes M, Twisk FN, Kubera M, Ringel K. Evidence for inflammation and activa- tion of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syn- drome (ME/CFS): increased interleukin-1, tumor necrosis factor-α, PMN-elastase, lysozyme and neopterin. J Affect Disord. 2012;136(3):933-939. Epub 2011 Oct 4.


18. Franklin BS, Latz E. For gut's sake: NLRC4 inflammasomes distinguish friend from foe. Nat Immunol. 2012;13(5):429-431. doi: 10.1038/ni.2289.


19. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dys- biosis regulates progression of NAFLD and obesity. Nature. 2012;482(7384):179-185. doi: 10.1038/nature10809.


20. Martinon F, Mayor A, Tschopp J. The in- flammasomes: guardians of the body. Annu Rev Immunol. 2009;27:229-265.


21. Kroemer G, Galluzzi L, Brenner C. Mi- tochondrial membrane permeabilization in cell death. Physiol Rev. 2007;87(1):99-163.


22. Maes M. Inflammatory and oxi-


dative and nitrosative stress pathways un- derpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry. 2009;22(1):75-83.


23. Kelly D, Delday MI, Mulder I. Microbes and microbial effector molecules in treat- ment of inflammatory disorders. Immunol Rev. 2012;245(1):27-44.


24. Avellaneda Fernández A, Pérez Martín A, Izquierdo Martínez M, Arruti Bustillo M, Barbado Hernández FJ, de la Cruz Labrado J, Díaz-Delgado Peñas R, Gutiérrez Rivas E, Palacín Delgado C, Rivera Redondo J, Ramón Giménez JR. Chronic fatigue syn- drome: aetiology, diagnosis and treatment. BMC Psychiatry. 2009 Oct 23;9 Suppl 1:S1. Review.


25. Nicolson, G.L. and Ellithrope, R. Lipid replacement and antioxidant nutritional therapy for restoring mitochondrial func- tion and reducing fatigue in chronic fatigue syndrome and other fatiguing illnesses. J. Chronic Fatigue Syndr. 2006;13(1): 57-68.


26. Ellithorpe RA, Settineri R, Mitchell CA, Jacques B, Ellithorpe E, Nicolson GL. Lipid replacement therapy drink containing a glycophospholipid formulation rapidly and significantly reduces fatigue while improv- ing energy and mental clarity. Funct Food Health Dis. 2011;1(8): 245-254.


27. Nicolson GL, Ellithorpe RR, Ayson- Mitchell C, Jacques B, Settineri R. Lipid Replacement Therapy with a Glycophos- pholipid-Antioxidant-Vitamin Formulation Significantly Reduces Fatigue Within One Week. J Am Nutraceut Assoc. 2010;13(1):10- 14


28. Nicolson GL, Ellithorpe R and Settineri


R. Blood homocysteine levels are signifi- cantly reduced with a glycophospholipid formulation (NTFactor® plus vitamin B- complex): a retrospective study in older subjects. Paper in Preparation.


29. Piper BF, Dibble SL, Dodd MJ, Weiss MC, Slaughter RE, Paul SM. The revised Piper Fatigue Scale: psychometric evalu- ation in women with breast cancer. Oncol Nurs Forum. 1998;25(4):677-684.


30. Agadjanyan M, Vasilevko V, Ghochikyan A, Berns P, Kesslak P, Settineri R, Nicolson GL. Nutritional supplement (NTFactor) re- stores mitochondrial function and reduces moderately severe fatigue in aged subjects. J Chronic Fatigue Syndr 2003;11(3):23-26.


31. Tschopp J. Mitochondria: Sover- eign of inflammation? Eur J Immu- nol. 2011;41(5):1196-1202. doi: 10.1002/ eji.201141436.


32. Franchi L, Muñoz-Planillo R, Núñez G. Sensing and reacting to microbes through the inflammasomes. Nat Immunol. 2012;13(4):325-332. doi: 10.1038/ni.2231.


33. Rakoff-Nahoum S, Paglino J, Eslami- Varzaneh F, Edberg S, Medzhitov R. Recog- nition of commensal microflora by toll-like receptors is required for intestinal homeo- stasis.Cell. 2004;118(2):229-241.


34. Lakhan SE, Kirchgessner A. Gut inflam- mation in chronic fatigue syndrome. Nutr Metab (Lond). 2010;7:79.


35. Circu ML, Aw TY. Intestinal redox biol- ogy and oxidative stress. Semin Cell Dev Biol. 2012; Mar 30. [Epub ahead of print]


36. Maes M. Inflammatory and oxidative and nitrosative stress pathways underpin- ning chronic fatigue, somatization and psy- chosomatic symptoms. Curr Opin Psychia- try. 2009;22(1):75-83.


37. Korecka A, Arulampalam V. The gut microbiome: scourge, sentinel or spectator? J Oral Microbiol. 2012;4. doi: 10.3402/jom. v4i0.9367. Epub 2012 Feb 21.


38. Scrivo R, Vasile M, Bartosiewicz I, Vale- sini G. Inflammation as "common soil" of the multifactorial diseases. Autoimmun Rev. 2011;10(7):369-374. Epub 2010 Dec 30. Review.


39. Dantzer R, O'Connor JC, Freund GG, Johnson RW, Kelley KW: From inflamma- tion to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci. 2008;9:46-56.


40. Raison CL, Lin JM, Reeves WC: Asso- ciation of peripheral inflammatory markers with chronic fatigue in a population-based sample. Brain Behav Immun. 2009;23:327- 337.


41. Wu HJ, Wu E. The role of gut microbiota in immune homeostasis and autoimmunity. Gut Microbes. 2012 ;3(1). [Epub ahead of print]


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20